• Gili Hart
    Gili HartCEO

    Gili Hart is a Biotech executive serving as the CEO of Mitoconix Bio since Oct. 2017. Prior to that she served as OPKO Biologic’s General Manager, since 2014. Dr. Hart brings extensive experience in managing critical global programs ranging from preclinical work through Phase 3 clinical trials.  Dr. Hart has broad experience in global regulatory strategic planning , interactions and partnering deals with large-pharma, public company road shows and financing. Dr. Hart served as VP of pre-clinical and clinical pharmacology in PROLOR Biotech during  2013 -2009, and before that as a Senior Director.  During 2005-2007, Dr. Hart was a research fellow in the Immunology Department at the Weizmann Institute and later at Yale University’s School of Medicine. She received her PhD cum laude from the Weizmann institute of Science and also graduated summa cum laude from the Technion with a Biotechnology Engineering degree.

    • Eyal Neria, PhD
      Eyal Neria, PhDCoo

      Dr. Neria is a science and business leader with over 20 years of experience guiding and leading biopharma research and development. Dr. Neria joined Mitoconix in 2016 and most recently was VP R&D Planning & Control and VP Therapeutics Development at Compugen Ltd. Previously, he held leadership positions in drug discovery and development at Peptera Pharmaceuticals, ProChon Biotech, Mindset Biopharmaceuticals and Silicon Graphics Biomedical. Dr. Neria has PhD in chemical physics from Tel-Aviv University and postdoctoral research at Harvard University with Prof. Karplus, 2013 Nobel laureate.

      • Lior Weissman
        Lior WeissmanVP R&D

        Dr. Lior Weissman joined Mitoconix Bio as Vice President, Research & Development, in Sep 2017. He has 10 years scientific and managerial experience in leading the development of innovative biopharmaceutical and drug-device combination products. Prior to joining Mitoconix, from 2008 to 2017, Dr. Weissman served in several R&D leadership roles at Omrix Biopharmaceuticals, a Johnson and Johnson company, most recently Senior Principal Scientist & Projects leader. He brings experience is managing multidisciplinary groups of scientists, global cross-functional project teams, and sub-contractors during various stages of drug development. Dr. Weissman received his Ph.D. in Biochemistry from Tel Aviv University, followed by postdoctoral research on neurodegeneration at the National Institutes of Health (NIH), USA.

        • Danny Fishelovitch
          Danny FishelovitchDirector of CMC

          Dr. Danny Fishelovitch has more than 10 years of experience in the pharmaceutical industry. He leads the Chemistry, Manufacturing and Controls (CMC) at Mitoconix Bio. Previously, he worked for approximately 4 years at Neuroderm Ltd. that was acquired by Mitsubishi Tanabe Pharma where he served at various positions such as Head of CMC, CMC manager and project manager. Prior to that, Danny was a CMC leader and a formulator researcher at Teva pharmaceuticals Ltd. Innovative R&D.

          Danny specializes in the development of various sterile and solid dosage forms as well as drug device combination. In addition, Danny has extensive experience in the scale-up and optimization of manufacturing processes by applying Quality-by-Design methodology.

          Danny is a pharmacist and computer scientist by training and holds a Ph.D. in Structural Bioinformatics from the Tel-Aviv University. He is an author of eight published scientific papers.